- Home
- HGV vs AKRO Comparison
HGV vs AKRO Comparison
Compare HGV & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGV
- AKRO
- Stock Information
- Founded
- HGV 1992
- AKRO 2017
- Country
- HGV United States
- AKRO United States
- Employees
- HGV N/A
- AKRO N/A
- Industry
- HGV Hotels/Resorts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HGV Consumer Discretionary
- AKRO Health Care
- Exchange
- HGV Nasdaq
- AKRO Nasdaq
- Market Cap
- HGV 3.7B
- AKRO 3.7B
- IPO Year
- HGV N/A
- AKRO 2019
- Fundamental
- Price
- HGV $40.29
- AKRO $54.12
- Analyst Decision
- HGV Buy
- AKRO Buy
- Analyst Count
- HGV 7
- AKRO 10
- Target Price
- HGV $51.29
- AKRO $73.56
- AVG Volume (30 Days)
- HGV 1.0M
- AKRO 1.8M
- Earning Date
- HGV 10-30-2025
- AKRO 11-07-2025
- Dividend Yield
- HGV N/A
- AKRO N/A
- EPS Growth
- HGV N/A
- AKRO N/A
- EPS
- HGV 0.56
- AKRO N/A
- Revenue
- HGV $4,470,000,000.00
- AKRO N/A
- Revenue This Year
- HGV $15.92
- AKRO N/A
- Revenue Next Year
- HGV $8.17
- AKRO N/A
- P/E Ratio
- HGV $72.26
- AKRO N/A
- Revenue Growth
- HGV 5.47
- AKRO N/A
- 52 Week Low
- HGV $30.59
- AKRO $21.34
- 52 Week High
- HGV $52.08
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- HGV 38.27
- AKRO 68.19
- Support Level
- HGV $39.09
- AKRO $53.90
- Resistance Level
- HGV $41.91
- AKRO $54.31
- Average True Range (ATR)
- HGV 1.44
- AKRO 0.23
- MACD
- HGV -0.39
- AKRO -0.25
- Stochastic Oscillator
- HGV 14.56
- AKRO 80.66
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.